Minzoya NDC 70748-322

NDC codes

FDA NDC Directory

Product NDC (as listed)70748-322Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70748-0322Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70748-322-14	70748032214	3 BLISTER PACK in 1 CARTON (70748-322-14) / 1 KIT in 1 BLISTER PACKMarketed from Jan 9, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Minzoya
Generic name (nonproprietary): levonorgestrel and ethinyl estradiol and ferrous bisglycinate
Dosage form: Kit
Labeler: Lupin Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217087
Marketing start: Jan 9, 2025
Listing expires: Dec 31, 2026
Identifiers: Product ID 70748-322_5b904f9d-2551-48bd-8945-d464ea5094c5SPL ID 5b904f9d-2551-48bd-8945-d464ea5094c5SPL set ID d5ebd7fa-c388-4619-8dcb-e862e4ce5285RxCUI 242297, 2672922, 2672923, 2699611UPC 0370748322116

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N470748032214 followed by a unit qualifier and the quantity

Package 70748-0322-14. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 9, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Minzoya™ is indicated for use by females of reproductive potential to prevent pregnancy. Minzoya is a progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)